Enter PROTAC (Proteolysis Targeting Chimera) technology, a transformative approach that diverges fundamentally from traditional inhibition by harnessing the cell’s own ubiquitin-proteasome system to selectively degrade the LSD1 enzyme. PROTAC molecules operate catalytically, tethering the target protein to an E3 ubiquitin ligase which flags it for destruction. This elegant mechanism ensures profound and durable depletion of LSD1 at lower compound concentrations compared to occupancy-driven inhibitors. Such catalytic degradation promises not only heightened efficacy but also reduced emergence of drug resistance and diminished off-target toxicities, positioning PROTACs as a next-generation therapeutic platform in oncology.

In this groundbreaking study, the research team engineered a series of PROTAC compounds by fusing an LSD1-binding moiety named LI-1 with the cereblon (CRBN)-recruiting ligand thalidomide via linkers of varying lengths. Through meticulous structure-activity relationship (SAR) investigations, a candidate designated LD-110 surfaced as the most potent and selective degrader of LSD1. Biochemical assays revealed that LD-110 substantially diminished LSD1 protein levels in breast and lung cancer cell lines in both a time-dependent and dose-dependent fashion. Notably, the half-maximal degradation concentrations (DC₅₀) of LD-110 were impressively low in MDA-MB-231 and MDA-MB-453 breast cancer cells, registering at 9.54 and 7.08 nanomolar, respectively. Although lung cancer H520 cells exhibited a higher DC₅₀ of 446 nanomolar, this still represents significant efficacy given the challenge of targeting non-hematological tumors.

Validation of the underlying degradation mechanism was achieved through rigorous control experiments. The authors demonstrated that the proteasome inhibitor MG132 and the neddylation inhibitor MLN4924 effectively abrogated LD-110-induced LSD1 degradation, confirming the critical involvement of the ubiquitin-proteasome system and the CRBN E3 ligase pathway. Furthermore, competitive inhibition with the LI-1 warhead and thalidomide ligand prevented degradation, and a methylated analog of LD-110 (LD-110Me), incapable of binding CRBN, failed to induce either LSD1 degradation or downstream substrate accumulation. These findings collectively solidify that LD-110 functions as a bona fide PROTAC, exploiting CRBN recruitment to catalyze targeted proteostasis.

Beyond biochemical validation, the anti-proliferative effects of LD-110 were striking. The compound exhibited potent growth inhibition across diverse cancer cell lines, yielding half-maximal inhibitory concentrations (IC₅₀) ranging broadly but often in the sub-micromolar range. Of equal importance, pharmacokinetic profiling demonstrated that LD-110 possesses favorable in vivo characteristics, including bioavailability and metabolic stability, which translated into marked tumor growth suppression in both breast and lung cancer xenograft models. Remarkably, this potent anti-tumor activity was achieved without detectable systemic toxicity, suggesting an attractive therapeutic window for further development.

Delving into the mechanistic underpinnings of LD-110’s cytotoxicity revealed a sophisticated orchestration of cellular stress pathways. LD-110 was found to induce apoptotic cell death primarily via triggering endoplasmic reticulum (ER) stress, converging on activation of the ATF4-CHOP axis—a central regulator of stress-induced apoptosis. On one hand, transcriptional modulation stems from LSD1 degradation leading to increased H3K4 dimethylation (H3K4me2), which facilitates ATF4 gene expression. On the other hand, LD-110 also stimulates reactive oxygen species (ROS) production resulting in DNA damage, which activates the GCN2-eIF2α pathway to augment translational synthesis of ATF4 protein. This dual mechanism synergistically amplifies ATF4 levels, engaging downstream apoptotic effectors.

The ATF4-CHOP pathway modulates critical determinants of cell fate by rebalancing members of the BCL-2 protein family. Specifically, LD-110 elevates the expression of NOXA, a potent pro-apoptotic factor, while concomitantly reducing MCL1, an anti-apoptotic protein that often confers resistance to cell death. This shift in protein equilibrium decisively steers cancer cells toward programmed apoptosis, underpinning the robust anticancer effects observed.

Nonetheless, the use of CRBN as the E3 ligase recruitment element inherently carries limitations related to off-target degradation. CRBN naturally targets substrates such as GSPT1 and the IKZF family, which are not the intended therapeutic targets. Consistent with this, LD-110 also promoted degradation of GSPT1 alongside LSD1. Intriguingly, the researchers discovered that GSPT1 competes with LSD1 for LD-110 binding, thereby diminishing the degrader’s efficiency toward LSD1. Through siRNA-mediated knockdown of GSPT1, the inhibitory effect on LSD1 degradation was alleviated, resulting in enhanced LD-110 potency and more pronounced growth inhibition of cancer cells.

This observation suggests a compelling therapeutic strategy: combining LD-110 with a selective GSPT1 degrader could yield synergistic anti-tumor activity through dual pathway engagement. Such a combination may allow for dose reduction, potentially minimizing toxicity while maximizing efficacy—an elegant example of precision polypharmacology.

In summation, this investigation heralds LD-110 as a pioneering PROTAC molecule that effectively depletes LSD1, exhibiting significant anticancer activity in vitro and in vivo. The dual mechanism of inducing ER stress and modulating epigenetic marks represents a novel therapeutic angle to combat cancers characterized by LSD1 overexpression. With favorable pharmacokinetic and safety profiles, LD-110 stands poised as a promising candidate to advance into clinical development, potentially transforming the therapeutic landscape for patients afflicted with breast, lung, and possibly other cancers.

As the field of targeted protein degradation continues to revolutionize drug discovery, studies such as this provide compelling proof-of-concept that PROTACs can surpass the limitations of traditional inhibitors. By capitalizing on polyfunctional molecular design, researchers are opening avenues toward durable, selective, and potent cancer therapies that exploit intrinsic cellular machinery to disarm oncogenic drivers.

Future research will undoubtedly explore further optimization of linker chemistry, E3 ligase selection, and combination regimens with other targeted agents. Moreover, deciphering and mitigating off-target effects inherent to PROTAC technology remains a priority to maximize clinical benefit. The promising results reported here pave the way for a new era in epigenetic cancer therapy, leveraging protein degradation machinery to deliver precise, potent, and lasting tumor suppression.

Subject of Research: LSD1 Protein Degradation Using PROTAC Technology for Cancer Therapy

Article Title: Discovery of LD-110 as a Potent PROTAC Degrader of LSD1 with Therapeutic Efficacy in Breast and Lung Cancer Models

Web References:
10.1016/j.scib.2025.10.024

Keywords:
Life sciences, Health and medicine, Biochemistry, Cancer treatments

Breast cancer remains one of the most prevalent malignancies affecting women globally, with complex molecular underpinnings that challenge effective treatment. The latest study, conducted by Cai, Liu, and Yin, focuses on RPL17, a ribosomal protein primarily known for its role in protein synthesis, but increasingly recognized for its extraribosomal functions in cancer biology. By illuminating RPL17’s influence on breast cancer cell behavior, this research injects fresh momentum into the quest for novel molecular targets.

The study meticulously traces the trajectory of RPL17 expression in breast cancer cells, revealing heightened levels that correlate with tumor stage and metastatic potential. Unlike traditional ribosomal proteins, RPL17 appears to extend its function beyond ribosome assembly, engaging in signaling cascades that govern cell proliferation and survival. This dual functionality underscores its potential as both a biomarker and a therapeutic target.

Central to this discovery is the elucidation of MAPK (Mitogen-Activated Protein Kinase) signaling pathway activation mediated by RPL17. The MAPK pathway, a critical conduit in transmitting extracellular growth signals to the nucleus, governs essential cellular processes such as differentiation, proliferation, and apoptosis. Dysregulation of this pathway is a hallmark of numerous cancers, including breast cancer; thus, RPL17’s role in modulating MAPK activity adds a vital layer to the pathophysiological narrative.

Through sophisticated molecular assays and in vitro experimentation, the researchers demonstrated that upregulation of RPL17 triggers MAPK cascade activation, enhancing tumorigenic properties such as invasiveness, motility, and resistance to apoptotic stimuli. These insights suggest that RPL17 is not a passive bystander but a dynamic promoter of oncogenic signaling, propelling cancer progression.

Intriguingly, the study also explored the mechanistic intricacies of this relationship, revealing that RPL17 may interact with upstream regulators or scaffold proteins facilitating MAPK pathway activation. This complex interplay hints at a finely tuned regulatory network wherein RPL17 acts as a molecular hub, integrating cellular signals to enhance malignant phenotypes.

The implications of these findings extend well into clinical realms. Targeting RPL17 could disrupt aberrant MAPK signaling, potentially restraining tumor growth and metastasis. Given the limitations of current MAPK inhibitors, which often face issues like resistance and toxicity, modulating RPL17 presents a compelling alternative or adjunct strategy.

Moreover, the identification of RPL17 as a contributor to breast cancer progression provides a dual advantage. Beyond its therapeutic targeting potential, RPL17 expression levels could serve as a prognostic indicator, aiding clinicians in stratifying patients based on tumor aggressiveness and tailoring personalized treatment protocols.

Advancing into translational prospects, the study encourages the development of small molecule inhibitors or RNA-based therapeutics aimed at RPL17 modulation. Such interventions could potentiate existing treatment regimens, enhancing efficacy while minimizing adverse effects—a significant stride in precision oncology.

This research also resonates with broader oncological paradigms where ribosomal proteins are emerging as multifunctional entities influencing cancer biology. The integration of ribosomal protein dynamics within signal transduction frameworks like MAPK underscores the intricate connectivity of cellular machinery exploited by tumors.

Future investigations inspired by this work might explore the crosstalk between RPL17 and other signaling pathways, uncovering synergistic interactions that sustain tumorigenesis. Additionally, in vivo studies and clinical trials evaluating RPL17-targeted therapies will be essential to translate these promising findings into tangible patient benefits.

Importantly, the study prompts a reevaluation of ribosomal proteins beyond their canonical roles, positioning them as critical modulators in cancer’s molecular landscape. This paradigm shift could catalyze innovative approaches that harness these proteins for diagnostic and therapeutic advancements.

Ultimately, this research by Cai and colleagues not only enriches our understanding of breast cancer biology but also kindles hope for more effective interventions. By spotlighting RPL17 and its regulatory impact on MAPK signaling, the study paves the way for breakthroughs that could transform patient outcomes and usher in a new era of cancer treatment.

As the scientific community continues to unravel the complexities of cancer signaling networks, the insights gained from this investigation underscore the importance of integrating molecular biology with clinical oncology. Such interdisciplinary efforts hold the key to conquering one of medicine’s most formidable challenges.

In conclusion, the identification of RPL17 as a regulator of breast cancer progression through MAPK pathway activation marks a significant milestone. The multifaceted role of RPL17 accentuates the intricate molecular choreography guiding malignancy and highlights promising targets for future therapeutic intervention. This advancement stands as a testament to the relentless pursuit of knowledge driving cancer research towards innovative and life-saving solutions.

Subject of Research: Regulation of breast cancer progression by RPL17 and its association with MAPK signaling activation

Article Title: RPL17 regulates the progression of breast cancer accompanied by MAPK signaling activation

Article References:
Cai, Y., Liu, H. & Yin, G. RPL17 regulates the progression of breast cancer accompanied by MAPK signaling activation. Med Oncol 42, 550 (2025). https://doi.org/10.1007/s12032-025-03117-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03117-1

At the heart of this discovery lies RNA Polymerase I (Pol I), the enzyme responsible for transcribing ribosomal RNA genes—a vital step in the assembly of ribosomes, the cellular machinery that translates genetic codes into functional proteins. While aberrant ribosome biogenesis has historically been recognized as a hallmark of cancer, this study elucidates a previously unappreciated layer of complexity: the connection between rRNA synthesis and the regulation of RNA splicing, a process that enables a single gene to produce diverse protein variants through selective editing of precursor RNA transcripts.

Led by Dr. Marikki Laiho, an expert in Radiation Oncology and Molecular Radiation Sciences, the team demonstrated that pharmacological inhibition of Pol I instigates a unique cellular stress response that reprograms RNA splicing patterns in cancer cells. This reprogramming selectively impairs tumor growth by altering the production of protein isoforms crucial for cancer cell survival and proliferation. Central to this mechanism are ribosomal proteins RPL22 and its paralog RPL22L1, as well as the MDM4 protein, all of which participate in coordinating the dynamic crosstalk between ribosome biogenesis and splicing modulation.

The study employed BMH-21, a small molecule developed in collaboration with Johns Hopkins pharmacology specialists, to obstruct Pol I activity in a comprehensive panel of over 300 cancer cell lines. Strikingly, cancers harboring mutations in RPL22 or exhibiting elevated levels of RPL22L1 and MDM4 were particularly vulnerable to Pol I inhibition. Notably, these molecular alterations frequently occur in tumors characterized by mismatch repair deficiency (MMRd), a genetic condition involving defects in DNA repair pathways. MMRd leads to an accumulation of genomic mutations and is commonly observed in colorectal, gastric, and uterine cancers, which often show resistance to standard therapies.

Further extending their findings beyond cell culture, the researchers evaluated a novel Pol I inhibitor, BOB-42, in animal tumor models that recapitulate patient-derived malignancies bearing these critical genetic signatures. Treatment with BOB-42 resulted in significant tumor suppression, with reductions in tumor size reaching up to 77% in aggressive melanoma and colorectal cancer models. These preclinical successes highlight the therapeutic potential of targeting the rRNA synthesis-splicing axis in cancers that evade existing treatment modalities.

Beyond its tumor-suppressive effects, the study suggests a compelling link between altered splicing patterns induced by Pol I inhibition and enhanced tumor immunogenicity. By reshaping the protein landscape presented by cancer cells, changes in RNA splicing may unmask novel tumor antigens, potentially improving recognition by the immune system. Consequently, the combination of Pol I inhibitors with immunotherapy agents could synergize to overcome immune evasion, a major hurdle in effective cancer treatment.

Dr. Laiho elaborated on this innovative concept, emphasizing the dual role of the ribosomal protein RPL22. Traditionally viewed as a structural ribosomal component, RPL22 also exerts regulatory control over selective RNA splicing. This dual functionality underscores a deeper level of cellular regulation wherein rRNA synthesis and splicing are intimately coordinated to dictate cancer cell behavior. Such a paradigm shift in understanding ribosome-related oncogenic processes could lead to transformative advances in precision oncology.

The implications of this work extend beyond therapeutic targeting of Pol I. By delineating the molecular underpinnings of cancer cells’ sensitivity to rRNA synthesis inhibition, the study offers insights into the vulnerabilities of mismatch repair-deficient tumors, which are often characterized by high mutation burden and poor prognosis. Therapeutic strategies that exploit these vulnerabilities could fill an urgent need for more effective treatments in this patient population.

Moreover, the discovery paves the way for future investigations into the role of ribosomal proteins in RNA metabolism and how their dysregulation contributes to tumorigenesis. The intersection of ribosome biogenesis with RNA splicing regulation represents a fertile frontier for molecular oncology research, promising new biomarkers and drug targets for a variety of cancers.

This pioneering research involved a multidisciplinary team, including insights from experts in cancer biology, pharmacology, and radiation oncology. Their collaborative efforts, complemented by funding from prominent institutions such as the National Institutes of Health and private foundations, exemplify the concerted push toward unraveling complex cancer vulnerabilities.

Acknowledging the translational potential of their findings, the researchers hold intellectual property rights related to Pol I inhibitors, underscoring the practical ambitions of bringing these discoveries from bench to bedside. Future clinical trials assessing the safety and efficacy of compounds like BMH-21 and BOB-42 will be critical to validate their therapeutic promise in cancer patients.

The study profoundly redefines our understanding of how ribosomal RNA synthesis intricately controls tumor cell physiology, revealing an exploitable Achilles’ heel within cancer’s machinery. By co-opting fundamental processes of RNA production and splicing regulation, this research charts a novel course for developing targeted, mechanism-based cancer therapies that could markedly improve patient outcomes in malignancies refractory to current interventions.

Subject of Research: Cancer Biology, Ribosome Biogenesis, RNA Splicing, Therapeutic Targeting
Article Title: Ribosomal RNA Synthesis and RNA Splicing Interplay as a Novel Tumor-Suppressive Pathway in Mismatch Repair-Deficient Cancers
News Publication Date: June 18, 2024
Web References:

• Johns Hopkins Kimmel Cancer Center: https://www.hopkinsmedicine.org/kimmel-cancer-center
• Department of Radiation Oncology and Molecular Radiation Sciences: https://www.hopkinsmedicine.org/radiation-oncology
• Cell Chemical Biology Journal: https://www.cell.com/cell-chemical-biology/home
  Image Credits: Courtesy of Cell Chemical Biology
  Keywords: Cells, Cancer Stem Cells, Ribosomal RNA, RNA Polymerase I, Mismatch Repair Deficiency, RPL22, RNA Splicing, Tumor Suppression, Immunotherapy, Cancer Therapeutics